Grifols will sell Igantibe in Spain, a medicine to prevent hepatitis B infection. The Catalan company has reached an agreement with the Ministry of Health and from now on the treatment can be prescribed in hospitals for both newborns and people who have not been previously vaccinated. After negotiations between administration and company, the pharmacy management has decided to grant a price of 233 eurosalthough another presentation of the therapy at 23.3 euros with a smaller amount of active ingredient.
During the next twelve months, Grifols will be able to dispense this medication under the conditions described, although Mónica García’s department has an ace up its sleeve in case it becomes necessary to modify any circumstance of the agreement. “There will be an annual review of sales and prices now set, to ensure that they are within the legally established parameters, and if not, proceed to their adjustment through the corresponding reduction,” says the ministry minutes.
Beyond the Grifols treatment, The minutes of the Drug Price Commission also bring good news for another Spanish company: Rovi. The López-Belmonte firm has managed to get one of the drugs it markets in Spain (the owner of the drug is the Austrian company Pharmaand) to extend its indications for use. From now on, the Rubraca brand, an oncological drug that is used for some ovarian cancer patients, can be used in other people with the same type of cancer who until now were excluded.
Rejected drugs
On the other hand, the Ministry of Health has decided not to include four medications in the public system. One of them is the antitumor Columvi, from Roche, which, in the opinion of Mónica García’s department, has a high price. “With respect to this medicine, the Commission agrees to propose its non-inclusion in the pharmaceutical provision, taking into account the therapeutic and social value of the medicine and its incremental clinical benefit, taking into account its cost-effectiveness relationship, as well as criteria for rationalizing public spending.” . Another medication, also for the same disease (lymphoma), that has been rejected for the same reasons has been Tepkinly, developed by Abbvie.
#Grifols #convinces #Health #sell #hepatitis #drug #Spain
